For the quarter ending 2026-03-31, ADPT had $7,106K increase in cash & cash equivalents over the period. -$10,333K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -20,015 | -13,579 | 9,545 | -55,423 |
| Depreciation expense | 3,418 | 3,766 | 3,977 | 8,391 |
| Noncash lease expense | 1,448 | 1,372 | 1,350 | 2,642 |
| Share-based compensation expense | 11,928 | 12,720 | 13,257 | 25,506 |
| Intangible assets amortization | 419 | 429 | 428 | 842 |
| Investment amortization | 136 | 288 | 516 | 1,708 |
| Impairment of long-lived assets | 347 | 0 | 0 | - |
| Inventory reserve | - | - | -6 | -46 |
| Write-off of inventory | -10 | 563 | - | - |
| Noncash interest expense | - | - | -1,728 | 287 |
| Revenue interest purchase agreement interest | 655 | 2,071 | - | - |
| Other Noncash Income Expense | -14 | -101 | -434 | -43 |
| Accounts receivable, net | -2,050 | 5,544 | 536 | 2,566 |
| Inventory | 1,315 | 10 | 1,347 | -359 |
| Prepaid expenses and other current assets | 824 | -799 | 2,524 | 8 |
| Accounts payable and accrued liabilities | -7,512 | 1,165 | 5,896 | -6,396 |
| Operating lease right-of-use assets and liabilities | -2,600 | -2,655 | -2,567 | -5,230 |
| Deferred revenue | 4,004 | 3,657 | -32,790 | -7,612 |
| Increase Decrease In Other Operating Capital Net | 98 | -137 | 0 | -5 |
| Net cash used in operating activities | -9,537 | 2,055 | -7,127 | -40,914 |
| Purchases of property and equipment | 796 | 636 | 409 | 1,914 |
| Purchases of marketable securities | 38,863 | 46,731 | 33,191 | 101,792 |
| Proceeds from maturities of marketable securities | 48,802 | 39,115 | 50,883 | 132,625 |
| Net cash provided by investing activities | 9,143 | -8,252 | 17,283 | 28,919 |
| Proceeds from exercise of stock options | 5,025 | 9,134 | 1,684 | 7,061 |
| Proceeds from capital contributions for digital biotechnologies, inc | 2,475 | 12,524 | - | - |
| Cash provided by financing activities | 7,500 | 21,658 | 1,684 | 7,061 |
| Net increase in cash, cash equivalents and restricted cash | 7,106 | 15,461 | 11,840 | -4,934 |
| Cash, cash equivalents and restricted cash at beginning of year | 73,184 | 57,723 | 50,817 | - |
| Cash, cash equivalents and restricted cash at end of period | 80,290 | 73,184 | 57,723 | - |
Adaptive Biotechnologies Corp (ADPT)
Adaptive Biotechnologies Corp (ADPT)